RANI

Rani Therapeutics Holdings, Inc.
CAPPED RATING

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc. (RANI) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
C
Factor Score 2.2 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.8
EV / EBITDA -0.8
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -33.9%
Price Return 12M -75.2%
Catalyst Signal 0.00
Market Cap $74.0M
TTM Revenue $4.9M
Price / Sales 15.2
ROE -172.1%

Historical Factor Score Progression

Held C for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) C (2.2) C+ (2.8) D+ (1.6) C+ (2.6) C (2.4)
2026-11-07 B- (2.9) D+ (1.7) C+ (2.8) C- (1.9) C+ (2.7) C (2.4)
2026-10-31 B- (2.9) D+ (1.7) C+ (2.8) C- (2.0) C+ (2.7) C (2.4)
2026-10-24 B- (2.9) D+ (1.7) C+ (2.8) D+ (1.7) C+ (2.6) C (2.3)
2026-10-17 B- (2.9) D+ (1.7) C+ (2.8) C+ (2.8) C+ (2.6) C+ (2.6)
Page 1 of 4